At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
Terpinen-4-ol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial
In Brief
A Phase 1 clinical trial evaluating Terpinen-4-ol and Placebo for Chronic Blepharitis. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This is a randomized clinical trial to determine the safety and efficacy of terpinen-4-ol (T4O), the most active ingredient of tea tree oil (TTO), in eradicating ocular demodicosis (reducing ocular demodex counts and achieving the clinical improvement with minimal or no irritation).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Blepharitis
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartFeb 2014
Primary CompletionJun 2015
Study CompletionJul 2015
TodayJul 2026
First PostedJul 23, 2012
Enrollment StartFeb 1, 2014
Primary CompletionJun 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.9 years ago
Interventions
Terpinen-4-oldrug
Lid scrub once or twice per day for one month.
Placeboother
Lid scrub once or twice per day for one month